FDA Pre-Submission: How the Q-Submission Program Works

Regulatory specialist preparing an FDA Pre-Submission with a timeline of feedback steps

On 29 May 2025, FDA issued the final guidance Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program. It followed a draft of 15 March 2024 and supersedes the June 2023 version. On 1 June 2026, FDA's eSTAR page announced that PreSTAR is available for voluntary use with more Q-Submission types.

A Pre-Submission only pays off when the questions are focused and asked before testing starts. This article covers what a Pre-Sub is, the other Q-Sub types, what to include, FDA's timelines, PreSTAR, and where a Pre-Sub fits before a De Novo or IDE.

What a Pre-Sub is

According to Section II.A of the guidance (PDF), a Pre-Submission is a formal written request for FDA feedback, answered in writing, or in writing followed by a meeting. It is used before a planned IDE, PMA, HDE, De Novo, 510(k), CLIA waiver, Dual submission, Accessory Classification Request, BLA or IND.

A Pre-Sub:

  • is voluntary;

  • is not a pre-review of data or of a draft submission;

  • does not guarantee a favourable decision on the later submission.

The guidance is nonbinding. Some questions belong elsewhere: a question about a device's classification goes to a 513(g) request, and a question about product jurisdiction to a Request for Designation (RFD) or Pre-RFD. Simple questions can often be answered informally.

Other Q-Submission types

Q-Sub type Use FDA timing
Submission Issue Request (SIR) Feedback on how to address deficiencies in a pending submission 21 or 70 days, as resources permit
Study Risk Determination Whether a planned device study is significant risk or non-significant risk 90 days
Informational Meeting Sharing information with FDA, without a request for feedback 90 days
PMA Day 100 Meeting Discussing a PMA's review status As set out in the guidance

Source: Q-Submission guidance, Sections II.B to II.F and Table 1.

The Q-Submission Program also tracks other requests, such as Breakthrough Device designation requests, Safer Technologies Program (STeP) requests and Accessory Classification Requests.

What to include

According to Section III.B, a Pre-Sub should contain:

  • Cover letter: contact details, the Q-Sub type, the feedback method (written, or written plus meeting), the meeting format, three or more proposed dates, and attendees;

  • Purpose of the request;

  • Device description and indications for use;

  • Regulatory history of the device;

  • Planned follow-on submission;

  • Background information on the topics;

  • Specific questions.

FDA advises no more than 3 to 4 substantial topics and typically 7 to 10 questions. Software, including SaMD, counts as a substantial topic.

In our view, fix the intended use and the pathway before asking about testing. FDA notes that questions depending on unresolved issues get weaker feedback.

FDA's timelines

Step FDA timing Source
Acceptance review or technical screening Within 15 days Q-Sub guidance
Meeting date agreed Within 30 days; FDA manager contact by day 40 if not Q-Sub guidance
Written feedback Within 70 days, or at least 5 days before the meeting Q-Sub guidance
Meeting Typically day 70 to 75; normally 1 hour Q-Sub guidance
Presentation slides At least 2 days before the meeting Q-Sub guidance
Submitter's draft minutes Within 15 days after the meeting Q-Sub guidance
FDA edits to minutes Within 30 days Q-Sub guidance
Edited minutes become final 15 days after FDA's edits, unless disputed Q-Sub guidance

Source: Q-Submission guidance (May 2025); all days are calendar days.

Tracking and electronic submission

Each Q-Sub receives a Q number. Follow-up requests are supplements (for example /S001), and additional information is an amendment (for example /A001). FDA recommends one active Q-Sub at a time per device, and citing the Q numbers in the cover letter of the later marketing submission.

Q-Subs are subject to eCopy. According to the eSTAR page, PreSTAR can be used voluntarily for Pre-Submissions and for Submission Issue Requests, Informational Meetings, Study Risk Determinations, PMA Day 100 Meetings and Accessory Classification Requests. FDA's May 2025 draft guidance on electronic Q-Submissions, once final, would set a timetable for requiring electronic Pre-Subs. No mandatory date applies yet.

How reliable is the feedback?

FDA intends its feedback not to change unless new issues arise. If more than one year has passed and the study has not started, check with FDA again. Minutes and materials may be released under the Freedom of Information Act.

In our view, treat Pre-Sub feedback and final minutes as controlled records, linked to the later submission.

Where a Pre-Sub fits

  • Before a De Novo: for example, to ask whether a proposed predicate is suitable or how to design the performance testing. Our article on De Novo review covers that route.

  • Before an IDE: to get feedback on a clinical study protocol. Our article on the investigational device exemption explains the IDE.

  • For AI-enabled devices: FDA encourages Q-Submission feedback on a proposed predetermined change control plan before the marketing submission. Our guide to the predetermined change control plan covers its content.

Our article on regulatory strategy for the EU and US covers how a Pre-Sub fits into the overall plan.

A hypothetical example

Hypothetical example: a Dutch company has AI image-analysis software and plans a De Novo request.

  1. Scope: it prepares one Pre-Sub with three topics: software, the clinical performance study and the PCCP.

  2. Questions: it asks about eight specific questions.

  3. Format: it uses PreSTAR and requests written feedback followed by a meeting.

  4. Minutes: it sends its draft minutes within 15 days of the meeting.

  5. Later: it cites the Q number in the cover letter of its De Novo request.

Conclusion

A Pre-Sub gets written FDA feedback, and optionally a meeting, on a planned submission. It works best with a fixed intended use and pathway, a small number of focused questions, and enough time before testing starts.

In our view, plan the Pre-Sub into the development schedule, keep the questions to what would change your plan, and file the feedback as a controlled record.

If you need help preparing a Pre-Submission, our regulatory strategy team can help, or contact MedQAIR.

Frequently asked questions

Is a Pre-Submission mandatory?

No. The Q-Submission Program is voluntary.

Can I ask FDA for my device's class in a Pre-Sub?

No. Classification questions should go to a 513(g) request for information.

How many questions should a Pre-Sub contain?

FDA advises no more than 3 to 4 substantial topics and typically 7 to 10 questions.

Written feedback or a meeting?

Either. FDA always gives written feedback; a meeting can follow it. Meetings normally last one hour.

Is PreSTAR required?

No. PreSTAR is voluntary for Q-Submissions. FDA's draft guidance on electronic Q-Submissions would set a timetable once final.

Is FDA's feedback binding?

No. FDA intends its feedback not to change unless new issues arise, but it does not guarantee a favourable decision on the later submission.

Latest Blogs

November 22, 2026

On 29 May 2025, FDA issued the final guidance Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission

November 21, 2026

The MDR of 5 April 2017 requires every manufacturer's quality management system to include "a strategy for regulatory compliance, including

November 20, 2026

On 7 January 2025, FDA issued the draft guidance Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.

logo

Unlock Your Quick Guide to AI Act
Compliance!

Explore AI-enabled SaMD requirements with our easy step-by-step guide.

Cookies help us improve your experience on our website. By using our site, you consent to the use of cookies as described in this policy.